Miho Oyasu
YOU?
Author Swipe
View article: Combination of Imvotamab and Loncastuximab Tesirine Shows Enhanced Anti‐Tumor Activity in a Preclinical Model of Non‐Hodgkin’s Lymphoma
Combination of Imvotamab and Loncastuximab Tesirine Shows Enhanced Anti‐Tumor Activity in a Preclinical Model of Non‐Hodgkin’s Lymphoma Open
Introduction: Non-Hodgkin's lymphoma (NHL) is among the most common cancers in the United States and Europe. Systemic chemoimmunotherapy, consisting of alkylating-based chemotherapy plus a CD20-directed monoclonal antibody therapy, is a ma…
View article: Figures S1-4 from A Novel, Fully Human Anti–fucosyl-GM1 Antibody Demonstrates Potent <i>In Vitro</i> and <i>In Vivo</i> Antitumor Activity in Preclinical Models of Small Cell Lung Cancer
Figures S1-4 from A Novel, Fully Human Anti–fucosyl-GM1 Antibody Demonstrates Potent <i>In Vitro</i> and <i>In Vivo</i> Antitumor Activity in Preclinical Models of Small Cell Lung Cancer Open
4 suppl figures on tumor models
View article: Tables S1-4 from A Novel, Fully Human Anti–fucosyl-GM1 Antibody Demonstrates Potent <i>In Vitro</i> and <i>In Vivo</i> Antitumor Activity in Preclinical Models of Small Cell Lung Cancer
Tables S1-4 from A Novel, Fully Human Anti–fucosyl-GM1 Antibody Demonstrates Potent <i>In Vitro</i> and <i>In Vivo</i> Antitumor Activity in Preclinical Models of Small Cell Lung Cancer Open
4 suppl tables on FucGM1 expression in lung cancer, binding, and mouse PK
View article: Figures S1-4 from A Novel, Fully Human Anti–fucosyl-GM1 Antibody Demonstrates Potent <i>In Vitro</i> and <i>In Vivo</i> Antitumor Activity in Preclinical Models of Small Cell Lung Cancer
Figures S1-4 from A Novel, Fully Human Anti–fucosyl-GM1 Antibody Demonstrates Potent <i>In Vitro</i> and <i>In Vivo</i> Antitumor Activity in Preclinical Models of Small Cell Lung Cancer Open
4 suppl figures on tumor models
View article: Tables S1-4 from A Novel, Fully Human Anti–fucosyl-GM1 Antibody Demonstrates Potent <i>In Vitro</i> and <i>In Vivo</i> Antitumor Activity in Preclinical Models of Small Cell Lung Cancer
Tables S1-4 from A Novel, Fully Human Anti–fucosyl-GM1 Antibody Demonstrates Potent <i>In Vitro</i> and <i>In Vivo</i> Antitumor Activity in Preclinical Models of Small Cell Lung Cancer Open
4 suppl tables on FucGM1 expression in lung cancer, binding, and mouse PK
View article: Data from A Novel, Fully Human Anti–fucosyl-GM1 Antibody Demonstrates Potent <i>In Vitro</i> and <i>In Vivo</i> Antitumor Activity in Preclinical Models of Small Cell Lung Cancer
Data from A Novel, Fully Human Anti–fucosyl-GM1 Antibody Demonstrates Potent <i>In Vitro</i> and <i>In Vivo</i> Antitumor Activity in Preclinical Models of Small Cell Lung Cancer Open
Purpose: The ganglioside fucosyl-GM1 (FucGM1) is a tumor-associated antigen expressed in a large percentage of human small cell lung cancer (SCLC) tumors, but absent in most normal adult tissues, making it a promising target in immuno-onco…
View article: Data from A Novel, Fully Human Anti–fucosyl-GM1 Antibody Demonstrates Potent <i>In Vitro</i> and <i>In Vivo</i> Antitumor Activity in Preclinical Models of Small Cell Lung Cancer
Data from A Novel, Fully Human Anti–fucosyl-GM1 Antibody Demonstrates Potent <i>In Vitro</i> and <i>In Vivo</i> Antitumor Activity in Preclinical Models of Small Cell Lung Cancer Open
Purpose: The ganglioside fucosyl-GM1 (FucGM1) is a tumor-associated antigen expressed in a large percentage of human small cell lung cancer (SCLC) tumors, but absent in most normal adult tissues, making it a promising target in immuno-onco…
View article: 1215 IGM-7354, an anti-PD-L1/IL-15 IgM immunocytokine, activates and expands NK cells and effector memory CD8+ T cells in vivo
1215 IGM-7354, an anti-PD-L1/IL-15 IgM immunocytokine, activates and expands NK cells and effector memory CD8+ T cells in vivo Open
Background IGM-7354 is an engineered, humanized high affinity, high avidity anti-PD-L1 pentameric IgM antibody with an IL-15Rα chain and IL-15 fused to the joining (J) chain. IGM-7354 was designed to deliver IL-15-mediated stimulation of N…
View article: 711 IGM-7354 is an anti-PD-L1 IgM antibody and IL-15 cytokine fusion that enhances NK and CD8+ T cell proliferation and tumor cytotoxicity plus potently reverses T cell exhaustion
711 IGM-7354 is an anti-PD-L1 IgM antibody and IL-15 cytokine fusion that enhances NK and CD8+ T cell proliferation and tumor cytotoxicity plus potently reverses T cell exhaustion Open
Background While approved PD-1/PD-L1 inhibitory antibodies have demonstrated clinical efficacy in certain cancer patients, relapse following a primary response is often observed. Enhancing anti-tumor immune responses with an immunostimulat…
View article: A Novel, Fully Human Anti–fucosyl-GM1 Antibody Demonstrates Potent <i>In Vitro</i> and <i>In Vivo</i> Antitumor Activity in Preclinical Models of Small Cell Lung Cancer
A Novel, Fully Human Anti–fucosyl-GM1 Antibody Demonstrates Potent <i>In Vitro</i> and <i>In Vivo</i> Antitumor Activity in Preclinical Models of Small Cell Lung Cancer Open
Purpose: The ganglioside fucosyl-GM1 (FucGM1) is a tumor-associated antigen expressed in a large percentage of human small cell lung cancer (SCLC) tumors, but absent in most normal adult tissues, making it a promising target in immuno-onco…